Innoviva (NASDAQ:INVA) Shares Unloaded Rep. George Whitesides

Representative George Whitesides (D-California) recently sold shares of Innoviva, Inc. NASDAQ: INVA. In a filing disclosed on April 23rd, the Representative disclosed that they had sold between $250,001 and $500,000 in Innoviva stock on March 25th. The trade occurred in the Representative's "LORETTA WHITESIDES INDIVIDUAL" account.

Representative George Whitesides also recently made the following trade(s):

• Sold $100,001 - $250,000 in shares of Netflix NASDAQ: NFLX on 3/27/2025.
• Sold $100,001 - $250,000 in shares of Linde NASDAQ: LIN on 3/24/2025.
• Sold $100,001 - $250,000 in shares of Procter & Gamble NYSE: PG on 3/24/2025.
• Sold $1,001 - $15,000 in shares of Sandoz Group OTCMKTS: SDZNY on 3/24/2025.
• Sold $15,001 - $50,000 in shares of American Electric Power NASDAQ: AEP on 3/24/2025.
• Sold $50,001 - $100,000 in shares of Medtronic NYSE: MDT on 3/24/2025.
• Sold $100,001 - $250,000 in shares of McDonald's NYSE: MCD on 3/24/2025.
• Sold $15,001 - $50,000 in shares of Bank of America NYSE: BAC on 3/24/2025.
• Sold $15,001 - $50,000 in shares of Diageo NYSE: DEO on 3/24/2025.
• Sold $100,001 - $250,000 in shares of Coca-Cola NYSE: KO on 3/24/2025.

Innoviva Stock Performance

INVA traded down $0.04 on Thursday, hitting $18.65. The company had a trading volume of 522,577 shares, compared to its average volume of 633,281. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of 27.03 and a beta of 0.48. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.79 and a quick ratio of 1.64. The company's fifty day moving average price is $17.79 and its 200 day moving average price is $18.38. Innoviva, Inc. has a 1-year low of $15.07 and a 1-year high of $21.28.

Innoviva (NASDAQ:INVA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.57 earnings per share (EPS) for the quarter. Innoviva had a net margin of 18.31% and a return on equity of 20.84%. The business had revenue of $91.81 million during the quarter. Equities analysts predict that Innoviva, Inc. will post 0.33 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Alexander J. Denner sold 1,196,746 shares of the business's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $17.52, for a total value of $20,966,989.92. Following the sale, the insider now owns 5,658,705 shares of the company's stock, valued at $99,140,511.60. The trade was a 17.46 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.25% of the company's stock.

Hedge Funds Weigh In On Innoviva

Large investors have recently bought and sold shares of the stock. BOKF NA lifted its holdings in shares of Innoviva by 2.3% during the 4th quarter. BOKF NA now owns 28,648 shares of the biotechnology company's stock worth $495,000 after acquiring an additional 641 shares during the period. Illinois Municipal Retirement Fund raised its position in Innoviva by 2.8% in the fourth quarter. Illinois Municipal Retirement Fund now owns 29,066 shares of the biotechnology company's stock worth $504,000 after purchasing an additional 784 shares in the last quarter. Farther Finance Advisors LLC raised its position in Innoviva by 10.3% in the first quarter. Farther Finance Advisors LLC now owns 8,516 shares of the biotechnology company's stock worth $153,000 after purchasing an additional 795 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Innoviva by 3.8% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,490 shares of the biotechnology company's stock worth $546,000 after purchasing an additional 1,162 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Innoviva by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,274 shares of the biotechnology company's stock valued at $230,000 after purchasing an additional 1,241 shares in the last quarter. 99.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

INVA has been the topic of several research analyst reports. StockNews.com raised Innoviva from a "hold" rating to a "buy" rating in a research report on Wednesday. Scotiabank began coverage on Innoviva in a report on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 target price on the stock.

About Representative Whitesides

George Whitesides (Democratic Party) is a member of the U.S. House, representing California's 27th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Whitesides (Democratic Party) ran for election to the U.S. House to represent California's 27th Congressional District. He won in the general election on November 5, 2024. George Whitesides earned a bachelor's degree in public and international affairs from Princeton University in 1996 and a master's degree in remote sensing and GIS from the University of Cambridge in 2000. His career experience includes working as the chief of staff for NASA during the administration of President Barack Obama (D) and the CEO of human spaceflight company Virgin Galactic. Whitesides co-founded Megafire Action, an organization dedicated to responding to wildfires. Whitesides co-chaired the Antelope Valley Covid-19 Task Force and joined the Antelope Valley Economic Development and Growth Enterprise (AV EDGE) as a board member.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.